A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

A. S. Paller, E. C. Siegfried, E. L. Simpson, M. J. Cork, B. Lockshin, M. P. Kosloski, M. A. Kamal, J. D. Davis, X. Sun, G. Pirozzi, N. M.H. Graham, A. Gadkari, L. Eckert, M. Ruddy, A. Bansal

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy'. Together they form a unique fingerprint.

Medicine & Life Sciences